Cargando…
Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity
The inhibition of the PCSK9/LDLR protein-protein interaction (PPI) is a promising strategy for developing new hypocholesterolemic agents. Recently, new antibodies have been approved for therapy, but the high cost and low patients’ compliance stimulate the development of alternatives. Starting from t...
Autores principales: | Lammi, Carmen, Sgrignani, Jacopo, Arnoldi, Anna, Grazioso, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382862/ https://www.ncbi.nlm.nih.gov/pubmed/30787312 http://dx.doi.org/10.1038/s41598-018-35819-0 |
Ejemplares similares
-
Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity
por: Lammi, Carmen, et al.
Publicado: (2022) -
Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells
por: Lammi, Carmen, et al.
Publicado: (2016) -
Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9(D374Y) Pathway: in vitro Characterization of its Dual Hypocholesterolemic Behavior
por: Lammi, Carmen, et al.
Publicado: (2019) -
Computational
Design, Synthesis, and Biological Evaluation
of Diimidazole Analogues Endowed with Dual PCSK9/HMG-CoAR-Inhibiting
Activity
por: Lammi, Carmen, et al.
Publicado: (2023) -
Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells
por: Macchi, Chiara, et al.
Publicado: (2021)